Literature DB >> 34887598

A Comprehensive Monitoring of Clozapine and Related Components in Clinical Practices. Saudi Arabian Scenario.

Jisha M Lucca1, Fatima M Al-Turaifi1, Al-Mubayedh Safyah1, Feras A Hamad Al-Awad1.   

Abstract

Objectives: Clozapine is considered as effective medication for treatment resistant schizophrenia. Due to its potential severe adverse effects' clozapine is underused in the clinical settings. Information's on clinical use and monitoring of clozapine is lacking in middle east. This research analysis clozapine prescription and monitoring patterns a in a university teaching hospital in Saudi Arabia. Experimental design: A retrospective observational study was conducted in the psychiatric department of a university hospital in Saudi Arabia. Patients on treatment with clozapine for minimum one year were reviewed and assessed for clozapine mandatory and non-mandatory requirements and its correlated factors. Observation: Majority of patients were male [(n = 36) 63%] and the average age of was 36.8 ± 12.3. TRS schizophrenia[(n = 49),85%] was the common indications. Prior to initiation of clozapine all recommended guidelines was followed for all patients (100%). In addition to the blood monitoring and vitals LFT (80.75%) and weight (87.77%) were frequently measured. Hematological work up performed routinely throughout initial 18 weeks (71.9 %) and every month (59.6%). Weight gain (29.8%) was the most documented adverse effects.
Conclusion: The current study explored experiences with clozapine prescribing practices in a university hospital KSA and suggest that clozapine prescription is completely adhered with already existing guidelines in terms of dosing and monitoring. There exist a careful balance of benefit and risk in term of adverse reaction of clozapine in the local population.
Copyright © 1964–2021 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States.

Entities:  

Keywords:  adverse reaction; clinical settings; clozapine; lab data; monitoring; saudi arabia

Mesh:

Substances:

Year:  2021        PMID: 34887598      PMCID: PMC8601762     

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  25 in total

1.  Psychopharmacology: underuse of evidence-based treatments in psychiatry.

Authors:  Mohamed Fayek; Calvin Flowers; Darin Signorelli; George Simpson
Journal:  Psychiatr Serv       Date:  2003-11       Impact factor: 3.084

Review 2.  Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine.

Authors:  Domenico De Berardis; Gabriella Rapini; Luigi Olivieri; Domenico Di Nicola; Carmine Tomasetti; Alessandro Valchera; Michele Fornaro; Fabio Di Fabio; Giampaolo Perna; Marco Di Nicola; Gianluca Serafini; Alessandro Carano; Maurizio Pompili; Federica Vellante; Laura Orsolini; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Ther Adv Drug Saf       Date:  2018-02-06

3.  Clozapine prescription pattern in patients with schizophrenia in Asia: The REAP survey (2016).

Authors:  Shi-Wei Xu; Min Dong; Qinge Zhang; Shu-Yu Yang; Lian-Yu Chen; Kang Sim; Yan-Ling He; Helen Fk Chiu; Norman Sartorius; Chay-Hoon Tan; Mian-Yoon Chong; Naotaka Shinfuku; Shih-Ku Lin; Chee H Ng; Gabor S Ungvari; Eunice Najoan; Roy Abraham Kallivayalil; Ruzita Jamaluddin; Afzal Javed; Hitoshi Iida; Thiha Swe; Bin Zhang; Yu-Tao Xiang
Journal:  Psychiatry Res       Date:  2019-03-16       Impact factor: 3.222

4.  Patterns of clozapine prescribing in a mental health service in New Zealand.

Authors:  Jeff Harrison; Minna Janlöv; Amanda J Wheeler
Journal:  Pharm World Sci       Date:  2010-06-06

5.  "Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.

Authors:  F A Mustafa; J G Burke; S S Abukmeil; J J Scanlon; M Cox
Journal:  Pharmacopsychiatry       Date:  2014-11-06       Impact factor: 5.788

6.  Clozapine-induced blood dyscrasias in Saudi Arab patients.

Authors:  Norah O Abanmy; Afnan Al-Jaloud; Aisha Al-Jabr; Rana Al-Ruwaisan; Walaa Al-Saeed; Solafa Fatani
Journal:  Int J Clin Pharm       Date:  2014-06-12

7.  Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1-12.5 Years.

Authors:  Jentien M Vermeulen; Geeske van Rooijen; Marita P J van de Kerkhof; Arjen L Sutterland; Christoph U Correll; Lieuwe de Haan
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

8.  Barriers to using clozapine in treatment-resistant schizophrenia: systematic review.

Authors:  Saeed Farooq; Abid Choudry; Dan Cohen; Farooq Naeem; Muhammad Ayub
Journal:  BJPsych Bull       Date:  2018-09-28

9.  Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders.

Authors:  J Leijala; O Kampman; J Suvisaari; S Eskelinen
Journal:  BMC Psychiatry       Date:  2021-01-13       Impact factor: 3.630

Review 10.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors:  Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.